Current Report Filing (8-k)

---

---

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): May 5, 2016 (May 1, 2016)

 

CELLULAR BIOMEDICINE GROUP, INC.

(Exact name of registrant as specified in its charter)

 

Delaware		001-36498		86-1032927
(State or other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

 

19925 Stevens Creek Blvd., Suite 100 Cupertino, California		95014
(Address of Principal Executive Offices)		(Zip Code)

 

Registrant’s telephone number, including area code:      [phone]

 

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

---

---

 

 

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On May 1, 2016, Mr. Wei (William) Cao   notified Cellular Biomedicine Group, Inc. (the “Company”) of his decision to resign, for personal reasons, as a director of the Company.  Mr. Cao’s resignation became effective on the same day.

Prior to his resignation, Mr. Cao was a Class III director of the Company.  There were no disagreements between the Company and Mr. Cao on any matter relating to the Company’s operation, policies or practices that led to his decision to resign.

 

 

 

 

 

2

---

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

	Cellular Biomedicine Group, Inc.
Date: May 5, 2016	By:	/s/ Bizuo (Tony) Liu
		Bizuo (Tony) Liu Chief Executive Officer

 

 

 

 

 

 

3

---